Hong Kong Stock Exchange · Healthcare
Invest in Dawnrays Pharmaceutical (Holdings) stock from India
Indian and foreign residents can buy Dawnrays Pharmaceutical (Holdings) (2348) shares directly through Paasa.
By Paasa · Updated
Dawnrays Pharmaceutical (Holdings) at a glance
- Price
- HK$0.98+HK$0.01 (0.52%)
- Market cap
- HK$1.47B
- Day range
- HK$0.97 – HK$0.98
- P/E
- 5.46
- Dividend yield
- 6.46%
- Volume
- 112.00K
- 1 month
- -2.50%
- 6 months
- -13.72%
- YTD
- -20.08%
- 1 year
- -18.07%
- 5 years
- -37.90%
Dawnrays Pharmaceutical (Holdings) statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CN¥1.2B | CN¥1.1B | CN¥1.2B | CN¥1.3B | CN¥1.2B |
| Gross profit | CN¥557.4M | CN¥577.6M | CN¥641.5M | CN¥766.7M | CN¥675.4M |
| Operating income | CN¥229.6M | CN¥367.9M | CN¥277.4M | CN¥422.4M | CN¥380.8M |
| Net income | CN¥214.0M | CN¥564.9M | CN¥326.0M | CN¥358.1M | CN¥358.2M |
| Earnings per share | CN¥0.14 | CN¥0.38 | CN¥0.22 | CN¥0.24 | CN¥0.24 |
| EBITDA | CN¥343.7M | CN¥280.5M | CN¥498.9M | CN¥505.2M | CN¥433.9M |
| Total assets | CN¥4.0B | CN¥4.0B | CN¥3.6B | CN¥3.7B | CN¥3.3B |
| Total debt | CN¥77.5M | CN¥34.7M | CN¥120.5M | CN¥8.4M | CN¥23.5M |
| Cash and short-term investments | CN¥1.6B | CN¥1.4B | CN¥1.1B | CN¥993.0M | CN¥830.2M |
| Shareholders' equity | CN¥3.4B | CN¥3.3B | CN¥2.9B | CN¥2.6B | CN¥2.4B |
| Operating cash flow | CN¥355.4M | CN¥220.2M | CN¥338.4M | CN¥434.3M | CN¥393.1M |
| Free cash flow | CN¥236.0M | CN¥44.6M | CN¥126.4M | CN¥229.9M | CN¥80.1M |
| Capital expenditure | −CN¥119.4M | −CN¥175.6M | −CN¥212.0M | −CN¥204.4M | −CN¥313.1M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CNY; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| CPBIO | 3839.HK | HK$8.10 | HK$1.95B |
| Chaoju Eye Care | 2219.HK | HK$2.42 | HK$1.68B |
| Golden Throat | 6896.HK | HK$1.97 | HK$1.45B |
| Zhaoke Ophthalmology | 6622.HK | HK$2.52 | HK$1.38B |
| Jilin Province Huinan Changlong Bio-pharmacy | 8049.HK | HK$2.39 | HK$1.34B |
| JBM (Healthcare) | 2161.HK | HK$1.64 | HK$1.34B |
| Rici Healthcare | 1526.HK | HK$0.84 | HK$1.33B |
| Essex Bio-Technology | 1061.HK | HK$2.09 | HK$1.18B |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Dawnrays Pharmaceutical (Holdings) from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to HKD when you buy.
Step 3
Search 2348 and buy
Find Dawnrays Pharmaceutical (Holdings) by name or by its ticker, 2348, and place your order. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
Why invest in Dawnrays Pharmaceutical (Holdings) from India
What Dawnrays Pharmaceutical (Holdings) does
Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets. Its operations are divided into two main divisions: Intermediates and Bulk Medicines, and Finished Drugs. Dawnrays Pharmaceutical (Holdings) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Dawnrays Pharmaceutical (Holdings) stock from India?
Yes. Indian residents and NRIs can buy Dawnrays Pharmaceutical (Holdings) (2348) shares directly through Paasa. Dawnrays Pharmaceutical (Holdings) is listed on the Hong Kong Stock Exchange, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Dawnrays Pharmaceutical (Holdings) share?
Usually more than one, and not a fraction: many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. At HK$0.98 a share, size the order by the lot, not by the share.
What tax do I pay in India when I sell Dawnrays Pharmaceutical (Holdings) shares?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the HKD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.
Would my heirs owe estate tax on Dawnrays Pharmaceutical (Holdings) shares?
Hong Kong has no estate duty. That is the source-country side; the shares themselves pass on like any other asset you hold in your own name.